<DOC>
	<DOCNO>NCT02716311</DOCNO>
	<brief_summary>Until recently , first line treatment metastatic Non Small Cell Lung Cancer ( NSCLC ) platine-based chemotherapy . It change discovery EGFR ( Epidermal Growth Factor Receptor ) mutation associate treatment Tyrosine Kinase Inhibitor ( TKI ) EGFR . The superiority EGFR TKI chemotherapy EGFR mutate patient prove several phase III trial gefitinib , erlotinib afatinib . Nevertheless , patient progress 9 12 month treatment due appearance treatment resistance . Afatinib irreversible EGFR TKI . It bind receptor permanently.Contrary erlotinib gefitinb inhibits EGFR , afatinib inhibits kinase activity HER family ( Human Epidermal growth factor Receptor ) . Nevertheless , proof afatinib delay appearance resistance . Cetuximab monoclonal antibody bind specifically EGFR . The double inhibition EGFR afatinib cetuximab demonstrate efficacy pre-clinical model . The hypothesis study combination cetuximab afatinib permit delay decrease appearance resistance .</brief_summary>
	<brief_title>Combination Cetuximab With Afatinib Patient With EGFR Mutated Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Principal Stage III IV NSCLC , non irradiable non operable Non squamous NSCLC histologically cytologically confirm No previous treatment NSCLC EGFR mutation ( exon 19 deletion , L858R mutation , G719X , L861Q S768I mutation exon 19 insertion ) Presence least one lesion measure PS 0 1 Principal Symptomatic brain metastasis require immediate radiotherapy T790M mutation exon 20 insertion Radiotherapy le 2 week prior randomization include symptomatic radiotherapy Interstitial pneumopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>EGFR</keyword>
	<keyword>Lung Cancer</keyword>
</DOC>